By 2030, there may be cancer and other illness vaccines available.

According to an article by The Guardian, a pharmaceutical company has announced that vaccines for various conditions including cancer, cardiovascular diseases, autoimmune diseases, and others could be available as early as 2030. Dr. Paul Burton, the chief medical officer of Moderna, expressed confidence in the firm’s ability to provide highly effective options for a variety of diseases within the next five years. He believes that mRNA therapies could offer solutions for rare diseases that currently have no available treatments.

Burton credits the success of these new treatments to the COVID-19 pandemic, which has accelerated the development and manufacturing of vaccines. Other experts, including Dr. Filip Dubovsky of Novavax and Prof. Andrew Pollard of the Oxford Vaccine Group and the UK’s Joint Committee on Vaccination and Immunisation, share Burton’s views on the significant advancements made in vaccine technology.

Moderna’s personalized cancer vaccine has been granted breakthrough therapy designation by the U.S. Food and Drug Administration, which means that its regulatory review will be expedited. Burton predicts that in 10 years, mRNA-based technology will allow for the identification of the genetic cause of diseases and their correction with relative ease.